Sandoz gains consent from the European Commission for its unique multiple sclerosis biosimilar, Tyruko® (natalizumab) in Europe.

Lantern Pharma Inc. has started Phase 1 clinical trial on its experimental drug, LP-184, for advanced solid tumors. This is part of the company's ongoing clinical drug development.

Escient Pharmaceuticals commences trial-based study of EP262, an innovative, orally-taken MRGPRX2 blocker for chronic inducible hives.

Data provided by Longhorn vaccine and diagnostics indicate that lhnvd-201 has neutralizing activity against covid-19 and influenza coinfection.

Appili Therapeutics a biodefense and infectious disease drug company, announced that its production and marketing partner, Saptalis Pharmaceuticals, received US FDA approval for Metronidazole Oral Suspension 500mg/5mL.

Nova Therapeutics, a biotech firm specializing in Influenza A treatments, received US FDA approval for its IND application for influenza A suppressant, VNT-101.

Merck reported that the phase III KEYNOTE-A39/EV-302 test halted disease progression in certain patients with local or metastatic urothelial cancer who hadn't received prior treatment.

Genmab Unveils EU Commission's Authorization for TEPKINLY® (epcoritamab) to Treat Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) in Adults.

Lutathera®, a radioligand therapy by Novartis, showed significant progression-free survival rates in initial stage advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Shanghai Henlius Biotech, Inc. has made a public announcement that the NMPA has given approval to the NDA for an innovative fresh indication of HANSIZHUANG (serplulimab injection).

SELLAS reveals uplifting preliminary findings in Lymphoma group from SLS009 Phase 1 Increasing-Dose Study, promoting progression to Phase 2 Clinical Experiment.

Krystal Biotech publicized that the U.S. FDA has given the green light for the Investigational New Drug application for KB408 to manage alpha-1 antitrypsin deficiency.